Tositumomab
- Generic Name
- Tositumomab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 208921-02-2
- Unique Ingredient Identifier
- 0343IGH41U
- Background
Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).
- Indication
For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)
- Associated Conditions
- -
- Associated Therapies
- -
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Duke University
- Target Recruit Count
- 39
- Registration Number
- NCT00577629
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath